RWE Study in the Treatment of Cervical Lesions of Various Etiology

Perfect Care Distribution345 enrolled

Overview

The aim of the study was to assess the post-market performance and tolerability of Cerviron® ovules in the treatment and management of cervical lesions of different etiologies. The study included clinical data related to aspect of lesions performed during routine colposcopy exams, the degree of re-epithelialization of the cervical mucosa, vaginal pH, pain level, and vaginal bleeding level.

This study is an observational, post-marketing study conducted between May-July 2021. The aim of the study was to assess the post-market performance and tolerability of Cerviron® ovules in the treatment and management of cervical lesions of different etiologies. The secondary objective of this clinical investigation is the assessment of performance of the medical device by clinical exam and patients' degree of satisfaction related to the use of the medical device. The study population included 345 participants aged 20-70 years with either a cervical lesion under treatment or with recent surgical removal of a cervical lesion.

Study Type

OBSERVATIONAL

Enrollment

345

Conditions

Cervical Lesion Vaginal Bleeding

Interventions

CervironDEVICE

Cerviron® is an invasive medical device of short-term use classified under annex VIII of the European Regulation 2017/745 as class IIb according to Rule 21 (devices composed of substances or of combinations of substances to be introduced into the human body via a body orifice or applied to the skin and absorbed by or locally dispersed in the human body). Cerviron® has a complex composition consisting of three topical pharmaceutical products - hexylresorcinol, collagen and bismuth subgallate - and four phytotherapeutic extracts - Calendula officinalis, Hydrastis canadensis, Thymus vulgaris extract and Curcuma longa. The Instructions for use specify its field of use as adjuvant in the treatment of acute and chronic vulvovaginitis of mechanical etiology, caused by changes of vaginal pH and changes of the vaginal flora and of cervical lesions of mechanical origin.

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with a clearly diagnosed non-infectious gynecological disease and patients with traumatic or surgical lesions. * Patients with either of the following medical history: trauma of the cervix, pain, bleeding after sexual intercourse, postpartum injuries or postoperative cervical lesions. Exclusion Criteria: * Patients with cervical cancer. * Patients with vulvar cancer

Locations (15)

Spitalul Clinic Dr. Ion Cantacuzino Bucharest

Bucharest, Romania

Med Life Humanitas Cluj-Napoca

Cluj-Napoca, Romania

Cabinet Medical - Dr. Saleh K. Majed

Craiova, Romania

Outcomes

Primary Outcomes

Rate of treatment-related adverse events in subjects participating in the clinical investigation

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

Time frame: 3 months

Secondary Outcomes

Clinical Performance assessed by the investigator

An assessment of the cervical lesions by gynecological examination (visual evaluation)

Time frame: 3 months

Patient Satisfaction

An assessment on a 5-point Likert scale to evaluate the degree of satisfaction after the treatment. The scale rates satisfaction from Very satisfied (maximum) to Very unsatisfied (minimum).

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.